High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes
| Autor: | Mack Roach, I-Chow Hsu, Alexander Gottschalk, Tania Kaprealian, Joycelyn L. Speight, Katsuto Shinohara, Vivian Weinberg |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_treatment Brachytherapy Fractionation Disease-Free Survival Statistics Nonparametric Prostate cancer Fiducial Markers Prostate Humans Medicine Radiology Nuclear Medicine and imaging Stage (cooking) Aged Neoplasm Staging Retrospective Studies Aged 80 and over Radiation business.industry Dose fractionation Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease High-Dose Rate Brachytherapy Radiation therapy Treatment Outcome medicine.anatomical_structure Oncology Dose Fractionation Radiation Neoplasm Grading business Nuclear medicine |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 82:222-227 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2010.09.021 |
| Popis: | Purpose This is a retrospective study comparing our experience with high-dose-rate (HDR) brachytherapy boost for prostate cancer, using two different fractionation schemes, 600 cGy × 3 fractions (patient group 1) and 950 cGy × 2 fractions (patient group 2). Methods and Materials A total of 165 patients were treated for prostate cancer using external beam radiation therapy up to a dose of 45 Gy, followed by an HDR brachytherapy prostate radiation boost. Between July 1997 and Nov 1999, 64 patients were treated with an HDR boost of 600 cGy × 3 fractions; and between June 2000 and Nov 2005, 101 patients were treated with an HDR boost of 950 cGy × 2 fractions. All but 9 patients had at least one of the following risk features: pretreatment prostate-specific antigen (PSA) level >10, a Gleason score ≥7, and/or clinical stage T3 disease. Results Median follow-up was 105 months for group 1 and 43 months for group 2. Patients in group 2 had a greater number of high-risk features than group 1 ( p = 0.02). Adjusted for comparable follow-up, there was no difference in biochemical no-evidence-of-disease (bNED) rate between the two fractionation scheme approaches, with 5-year Kaplan-Meier estimates of 93.5% in group 1 and 87.3% in group 2 ( p = 0.19). The 5-year estimates of progression-free survival were 86% for group 1 and 83% for group 2 ( p = 0.53). Among high-risk patients, there were no differences in bNED or PFS rate due to fractionation. Conclusions Results were excellent for both groups. Adjusted for comparable follow-up, no differences were found between groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|